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Microorganisms use quorum sensing (QS), a cell density dependent process, to communicate. 23 
This QS mode of interchange leads to the production of a variety of virulence factors, co-24 
ordination of complex bacterial behaviours, such as swarming motility, degradation of host 25 
tissue and biofilm formation. QS is implicated in numerous human infections and, 26 
consequently, researchers have sought ways of effectively inhibiting the process in 27 
pathogenic bacteria. Two decades ago, furanones were the first class of chemical compounds 28 
identified as Pseudomonas aeruginosa QS inhibitors (QSIs).  P. aeruginosa is a ubiquitous 29 
organism, capable of causing a wide range of infections in humans, including eye and ear 30 
infections, wound infections and potentially fatal bacteraemia and thus novel treatments 31 
against this organism are greatly needed. This review provides a brief background on QS and 32 
the use of furanones as QSIs. Based on the effectiveness of action, both in vivo and in vitro, 33 
we will explore the use of furanones as potential antimicrobial therapeutics and conclude 34 













Quorum sensing (QS) is a cell density-dependent method of bacterial communication and co-44 
ordination, which is seen in many species, including P. aeruginosa, V. fischeri and E. 45 
carotovora [1]. QS systems in these organisms are often associated with altered phenotypes 46 
[2] and the regulation of complex processes such as biofilm formation [3–7], swarming 47 
motility [8] and virulence gene expression including those coding for degradative enzymes 48 
[9]. In brief, quorum sensing bacteria constitutively express low molecular weight signalling 49 
molecules known as autoinducers. In gram-negative organisms, the primary autoinducers are 50 
a group of molecules known as the N-acyl homoserine lactones (AHL)[10]. These AHLs are 51 
produced and released by bacteria and accumulate in their extracelluar environment. Once a 52 
critical environmental AHL concentration is reached, the signalling molecules will interact 53 
with their cognate receptors and induce the expression of their target genes. The regulation 54 
of these target genes can result in the production of molecules, such as endotoxins and 55 
degradative enzymes [11–13] or down regulation of surface antigens, such as OprH [14] to 56 
avoid detection by a host’s immune system. Bacteria often have multiple QS systems, which 57 
work together in order to govern the organism’s virulence and behaviour. A good example of 58 
this is the model gram-negative organism P. aeruginosa, which utilises 3 distinct quorum 59 
sensing systems known as the Las, Rhl, PQS systems and one recently proposed system, the 60 
IQS system. [15] .  The Las QS system is responsible for the production of many virulence 61 
factors including the LasA, LasB, and Apr protease enzymes [16, 17]. While the Las QS system 62 
is only one QS system used by P. aeruginosa, it is typically thought of as being at the top of 63 
the QS hierarchy, primarily due to the fact that activation of the Las system causes a 64 
subsequent activation of both the Rhl and PQS systems[18, 19]. Activation of the Rhl QS 65 





involved in rhamnolipid, pyocyanin, and hydrogen cyanide production [20, 21]. As is the case 67 
with the Las quorum sensing system, the Rhl QS system is not wholly independent and it can 68 
be activated by the Las system, but can also supress the activation of the PQS system. This 69 
interrelation of the various QS systems allows P. aeruginosa to compensate for the loss or 70 
inhibition of one QS system and still remain virulent. The complexity of bacterial QS and the 71 
ability of many species to compensate for the loss of one or more QS systems makes 72 
exploiting the inhibition of quorum sensing a particularly challenging task.  73 
An overview of the QS process in P. aeruginosa is presented in Figure 1 For a comprehensive 74 
overview of bacterial quorum sensing, the reader is referred to two recent reviews [22, 23] 75 
 76 
Figure 1. Interrelation of the 3 primary quorum sensing systems (Las, Rhl and PQS) in the 77 
model gram-negative microorganism Pseudomonas aeruginosa. 1. Octododecanoyl 78 
homoserine lactone (OdDHL) accumulates in the extracellular environment and once a 79 
critical threshold is reached it diffuses back into the cell. 2. Here, the LasR interacts with, 80 
and causes dimerization of, the transcriptional activator, LasR .  3-4. The LasR/OdDHL 81 
complex then initiates transcription of numerous genes including lasI (thus producing more 82 
OdDHL), lasA (LasA protease) and lasB (LasB elastase). These products then either diffuse 83 
out or are actively effluxed from the cell. 5. The LasR/OdDHL complex also activates 84 
transcription of the rhlR and rhlI genes. 6. Transcription of rhlR results in the production of 85 
the transcriptional regulator protein RhlR and transcription of rhlI results in production of 86 
Butyryl homoserine lactone (BHL). 7. BHL diffuses from the cell and accumulates in the 87 
extracellular environment resulting in a second positive feedback loop. 8. As with OdDHL, 88 
BHL enters the cell and binds with RhlR to cause a conformational change. The RhlR/BHL 89 
complex then promotes the transcription of rhlI leading to an increased production of BHL 90 
as well as the transcription of genes causing production of rhamnolipids and pyocyanin. 9. 91 
The RhlR/BHR complex also plays a role in negatively regulating the PQS system. 10-12. 92 
Finally, the PQS quorum sensing system, responsible for the production of pyocyanin and 93 
hydrogen cyanide is activated by the LasR/OdDHL complex causing the transcription of pqsH 94 
gene that results in the production of the Pseudomonas quinolone signal (PQS) [24]. 13-14. 95 
PQS, in conjunction with the transcriptional regulator, PqsR, activates transcription of the 96 
pqsABCDE operon, positively regulating further transcription of rhlR and, via the pqsABCDE 97 
gene products, increasing expression of genes associated with production of hydrogen 98 






QS is important not only for bacterial survival but also in allowing bacteria to colonise and 101 
infect a host by, for example, promoting bacterial adhesion to host cells [25] Additionally, QS–102 
controlled behaviours, such as biofilm formation and virulence factor production, have been 103 
implicated in numerous health conditions including cystic fibrosis, development of chronic 104 
wounds and colonisation/infection of medical implants [26–28]. Biofilms, in particular are 105 
highly problematic in these conditions.  106 
Biofilm formation is a process by which planktonic cells form organised communities. They 107 
are encased in a self–produced polymeric substance, often attached to a biotic or abiotic 108 
surface [29]. Briefly, biofilms are formed when planktonic bacteria attach, first reversibly then 109 
irreversibly, to a surface. This attachment results in changes in the expression of multiple 110 
genes involved in the biofilm formation process, such as the genes involved in the production 111 
of the polymeric matrix that provides the biofilm structure and some virulence factors [30, 112 
31]. Bacterial cells begin to aggregate and form microcolonies, encased in the extracellular 113 
polymeric substance. These polymers are continually produced and gradually accumulate, 114 
while bacterial cells divide providing much of the three–dimensional structure of the biofilm. 115 
Finally, once the biofilm has matured, large quantities of surfactants, such as rhamnolipid, are 116 
produced. These surfactants allow the biofilm to disperse, thus returning some of its cells to 117 
a planktonic state [32]. Cells that have become planktonic again are then free to relocate and 118 
seed new biofilms. This dispersal may be brought about through the mature biofilm 119 
experiencing a damaging mechanical force or it may be triggered by environmental cues, such 120 
as an abundance of nutrients [33]. 121 
The role of QS in biofilm formation has been debated for some time with many published 122 





of biofilm development in P. aeruginosa. For example, QS–controlled twitching motility is 124 
involved in the formation of the microcolonies in the early stages of biofilm formation[34]. As 125 
well as having a role in microcolony formation through the regulation of twitching motility, 126 
QS has also been shown to be involved in the process of biofilm maturation and the formation 127 
and maintenance of its three–dimensional structure [32], thus making QS an attractive target 128 
for new therapies. 129 
One method of ameliorating the negative effect of processes, such as biofilm formation, is to 130 
inhibit the QS processes that control them, using compounds known as quorum sensing 131 
inhibitors (QSI). QSI include a range of natural and synthetic compounds that prevent 132 
autoinducers from binding to their cognate receptors, suppress the production of new 133 
autoinducers, or enzymatically degrade autoinducers before they are detected (also known 134 
as quorum quenching). In this review, we will focus on the potential utility of furanones as 135 
QSI. For a more general review of quorum sensing inhibitors, particularly their use as 136 
antibiofilm agents, the reader is referred to the recent work of Brackman and Coenye [35]. 137 
  138 
Furanones 139 
Furanones are a family of structurally related molecules characterised by the presence of a 5 140 
membered heterocyclic furan ring. Furanones are common in nature and are found in a wide 141 
variety of marine and terrestrial plants, including the red marine macroalga Delisia pulchra, 142 
strawberries and coffee [36, 37]. Some furanones are produced as a by-product of cooking 143 
food, for example in the Maillard reaction when baking bread, where they also act as flavour 144 
compounds [38, 39]. Furanones are also found in a number of fermented food products, 145 





fungi and species, such as Aspergillus spp. They are capable of producing furanone derivative 147 
compounds [41], which represent a potential new avenue of enquiry into QS inhibition. 148 
As well as being present in a number of natural sources, furanones can be chemically 149 
synthesised. Furanone derivatives have been chemically synthesised since the 1980s and 150 
synthesis often began with relatively simple compounds, such as ketones and dimethyl 151 
acetals or other simple organic precursors [42, 43]. Alternatively, modifications can be made 152 
to existing furanone compounds, as well as additions to existing furanone structures as will 153 
be discussed later in this review. Both natural and synthetic furanones have been shown to 154 
effectively inhibit QS but synthetic furanones offer the possibility of precise control over 155 
compound structure and, therefore, control of any potential off–target effects. 156 
Efficacy of furanones against non-human pathogens 157 
One of the earliest natural furanones to be discovered and characterised was 2,5-dimethy-4-158 
hydroxy-3(2H)-furanone. It is found in pineapple and was reported in 1965 by Rodin et al. 159 
[44]. Using gas chromatography and nuclear magnetic resonance spectroscopy, they 160 
determined that this aromatic compound must contain a cyclic five–membered ring structure 161 
in addition to an arrangement of side groups that the authors were unable to definitively 162 
characterise, despite similarities to a  previously synthesised compound tetrahydro-3,4,-163 
furandione [44, 45]. In spite of the characterisation of this and other furanone compounds, 164 
the structural similarities between furanones and gram-negative QS molecules was not 165 
realised until after the identification of autoinduction by Nealson et al. in 1970 and the 166 
structural characterisation of the chemical autoinducers (now known as N-acyl homoserine 167 
lactones or AHL) in Photobacterium fischeri by Eberhard et al. in 1981 [46, 47]. The P. fischeri 168 





six-carbon chain and was identified as N-(3-oxo-hexanoyl)-3-aminodihydro-2(3H)-furanone. 170 
Although the structure of furanones and AHL had both been known for more than a decade 171 
at this point, investigations into their anti–quorum sensing properties began only in 1993 172 
following the discovery of halogenated furanones in the marine alga Delisea pulchra [36]. As 173 
with the naturally occurring fruit furanones, these natural halogenated furanones were 174 
structurally similar to AHL. The similarity of the five membered ring structure found in both 175 
furanones and AHL, along with the ability of D. pulchra to resist epiphytic colonisation, 176 
prompted studies into the effects of these seaweed–derived furanones on AHL–mediated 177 
bacterial behaviours. Some of the first experiments showed furanone treatment greatly 178 
reduced Serratia liquifaciens swarming motility, as well as Vibrio spp. bioluminescence (up to 179 
100–fold) [48], providing evidence that furanones could modulate QS–mediated behaviours.   180 
Further investigation of QSI revealed that seaweed–derived furanones interfered with AHL 181 
mediated processes via displacement of the AHL signalling molecule from its cognate 182 
receptor. Using tritium–labelled AHL, Manefield et al. [49] showed that the addition of 183 
furanone to cultures of Escherichia coli pHK724 (overexpressing a recombinant LuxR AHL 184 
receptor protein) resulted in a dose–dependent decrease in the proportion of labelled AHL in 185 
the cells when compared to untreated cells. They also showed that addition of two 186 
different,although unnamed, furanones to a culture of E. coli pHK724 that was already 187 
saturated with 0.5 µM exogenous autoinducer reduced the proportion of autoinducer bound 188 
to the LuxR receptor by over 75%. Two–dimensional gel electrophoresis then revealed that 189 
protein synthesis in furanone–treated cells was largely unaffected, save for reductions in the 190 
abundance of several Lux QS system proteins tentatively identified as LuxA, LuxB and LuxD, 191 





It has  been shown by Welch et al. (2000) and Manfield et al. (2001) that, in Erwinia 193 
carotovora, treatment with an unnamed, seaweed derived, halogenated furanone (30 µM) 194 
reduced the secretion of virulence factors, including protease and cellulase. Furthermore, a 195 
dose–dependent response was observed between 10 µM and 40 µM, leading to a reduction 196 
in carbapenem production that was suggested to result from furanone–mediated 197 
interference in the quorum sensing–regulated production of the CarA and CarC proteins 198 
required for carbapenem-3-carboxylic acid production[50–52]. 199 
These reports showed that not only can natural furanones effectively inhibit quorum sensing, 200 
but that they could, in theory, be used to attenuate the virulence of some microorganisms. 201 
This leads logically to consideration of the potential of furanones in the battle against human 202 
pathogens. 203 
Efficacy of furanones against human pathogens 204 
In recent years, the majority of research into furanone–mediated QSI has focused primarily 205 
on the effects of these compounds on human pathogens and, in particular, the model 206 
organisms E. coli and Pseudomonas aeruginosa.  207 
Efficacy of furanones against Escherichia coli 208 
A natural furanone, known as (5Z)-4-bromo-5-(bromoethylene)-3-butyl-2(5H)-furanone 209 
(Figure 3), was demonstrated to inhibit bioluminescence in the marine organism Vibrio 210 
harveyi at concentrations between 16.13 µM and 32.26 µM. The same furanone also 211 
attenuated biofilm formation in E. coli, reducing average biofilm thickness by 55% and the 212 
number of viable cells by 87 % at a concentration of 164 µM. Additionally, lower furanone 213 
concentrations (64.5 µM) significantly reduced E. coli swarming motility [53]. This important 214 





phenomenon could be used to combat virulence in human pathogens. Investigations into the 216 
effects of synthetic brominated furanones showed that these compounds could also reduce 217 
E. coli biofilm thickness and surface coverage by up to 50% [54] and that, when applied at 50 218 
µM, could inhibit swarming motility and reduce biofilm production by up to 40 % in the food–219 
borne pathogen E.coli 0103: H2 [55, 56].  220 
Efficacy of furanones against Pseudomonas aeruginosa 221 
Natural furanones greatly reduce the production of P. aeruginosa virulence factors including 222 
protease (up to 43 %), chitinase and pyoverdine (by almost 100%) [57–59].  However, it 223 
becomes clear that the efficacy, and effect, of furanones in decreasing bacterial virulence may 224 
not be consistent. For example, the near total prevention of pyoverdine production by C-30, 225 
a synthetic derivative (Figure 3) of the natural seaweed–derived furanone, was reported by 226 
Hentzer et al. in 2003 [58]. The later work of Ren et al. (2005), however, demonstrated that  227 
both P. aeruginosa PAO1 and JB2 exhibited an increase in siderophore production when 228 
exposed to the natural furanone (5Z)-4-bromo-5-(bromoethylene)-3-butyl-2(5H)-furanone at 229 
concentrations between 20 µg mL-1 and 100 µg mL-1 (64.5–322.5 µM) [60]. This discrepancy 230 
is most likely due to the differences in structures of the furanone used. The natural furanone 231 
used by Ren et al. has a hydrocarbon chain bound to the furanone ring [61], whereas this is 232 
substituted for a single hydrogen in the synthetic furanone, C-30 [58] (Figure 3). Nonetheless, 233 
the observed differences in effects mediated by these two molecules suggest that alterations 234 
in the chemical structure of furanones or their derivatives result in significant differences in 235 
their QSI activity. 236 
Figure 3. Comparison of natural and synthetic furanone structures: (A) naturally occurring 237 
(seaweed–derived) furanone (5Z)-4-bromo-5-(bromoethylene)-3-butyl-2(5H)-furanone, (B) 238 
the synthetic furanone known as C-30. Both compounds exhibit similarities in structure, 239 





chain. The compounds have different biological activities, leading to the conclusion that 241 
changes in side group structure play a key role in determining furanone compound efficacy 242 
as QSI. 243 
 244 
In addition to their ability to reduce virulence factor production in a range of microorganisms, 245 
one of the most important effects of furanone compounds on P. aeruginosa is their ability to 246 
interfere with biofilm formation. Investigations in the early 2000s showed that two synthetic 247 
furanone derivatives in particular, C-56 and C-30, were highly effective in inhibiting P.  248 
aeruginosa biofilm formation [57, 58].  These furanones interfered with quorum sensing in 249 
both planktonic cultures and, more importantly, in established biofilms. While furanone C-56 250 
did not appear to affect the initial bacterial attachment stage of biofilm formation, cells 251 
treated with 5 µg mL-1 (28.5 µM) C-56 developed significantly thinner biofilms, exhibiting an 252 
approximate 37% reduction in overall thickness. The synthetic furanone–treated biofilms also 253 
appeared to be more sparsely populated than untreated biofilms and overall the data 254 
suggested that furanones might have a significant long–term effect on both biofilm formation 255 
and maintenance. This idea was further supported by the recent work of Choi et al. in 2014 256 
[59] who showed that, in PAO1, treatment with a natural furanone 4-hydroxy-2,5-dimethyl-257 
3(2H)–furanone (HDMF) reduced rhamnolipid production. Rhamnolipids are essential for 258 
maintenance of biofilm structure and integrity [32, 59] and PAO1 cells grown in the presence 259 
of either 0.1 µM or 1 µM HDMF formed biofilms, but with reduced biofilm biomass (27.8% 260 
and 42.6%, respectively). Treatment of 48 hour PAO1 biofilms with either 0.1 µM or 1 µM 261 
HDMF also led to subsequent 66.3% and 84.8% losses, respectively, of biofilm biomass over 262 
the following 48 hours, whereas untreated biofilms lost only ~50% of their biomass in the 263 
same time period. This data suggests that HDMF treatment accelerates the natural, post 48 264 





changed, as furanone–treated late–stage biofilms presented as poorly populated monolayers 266 
in comparison to the more natural 3D architecture and dense cell population of the untreated 267 
controls.  268 
Kim et al. (2008) showed that a synthetic furanone compound, named 5a, could efficiently 269 
reduce the initial attachment of planktonic P. aeruginosa cells to glass slides [62]. While no 270 
mechanism for the phenomenon was reported by the authors, the differences observed 271 
suggest that, although different furanones may inhibit QS and biofilm production, they may 272 
do so in quite different ways, possibly by acting upon different elements of the QS–mediated 273 
processes that lead to biofilm formation. 274 
Numerous other furanone compounds can also effectively reduce biofilm formation in PAO1.  275 
Reductions of up to 43 % were shown by Shetye et al. [54] using a range of synthetic 276 
brominated furanones. Four of these in particular were found to be effective in reducing 277 
either E. coli or P. aeruginosa biofilm formation. Despite their apparent efficacy, they have 278 
not been characterised as thoroughly as C-30 and C-56.  279 
Furanone compounds have another important effect on P. aeruginosa, specifically on so–280 
called “persister cells”–a type of largely dormant and consequently less antibiotic–sensitive 281 
cell found in biofilms. Persister cells are believed to be involved in maintaining chronic and 282 
recurrent infections, particularly in conditions such as cystic fibrosis [63, 64]. Certain 283 
furanones, however, can sensitise PAO1 persister cells to antibiotics, reducing their numbers 284 
and making biofilm eradication more likely. Treatment with between 5 µg mL-1 and 100 µg 285 
mL-1 of a synthetic brominated furanone, (Z-4-bromo-5-(bromoethylene-3-methylfurn-2(5H)-286 
one, resulted in a dose–dependent reduction in planktonic PAO1 persister cell numbers from 287 





of persister cells was reduced, total cell numbers were not affected by the furanone 289 
treatment. Importantly, this reduction in persister cells also occurred in surface–attached 290 
biofilms, and here, a 2 log10 reduction in numbers from 1 × 104 CFU mL-1 to 1 × 102 CFU mL-1 291 
was observed following treatment with 60 µg mL-1 of the synthetic brominated furanone. In 292 
addition, a relatively low dose of furanone also increased the efficacy of tobramycin and 293 
ciprofloxacin in killing persister cells: 5 µg mL-1 of synthetic brominated furanone followed by 294 
tobramycin treatment reduced persister cell numbers by over 99.9 %, an order of magnitude 295 
greater than antibiotic alone, while treatment with ciprofloxacin reduced persister cell 296 
numbers by approximately 90 % compared to a 50 % reduction with antibiotic only. Thus, 297 
furanone addition potentiated biofilm persister cell killing by reducing the antibiotic tolerance 298 
of the cells. Two further, structurally distinct, furanone compounds also led to a reduction in 299 
persister cell numbers. However, it was also observed that several other distinct furanones, 300 
while capable QSI, had no effect on persister cells [65, 66]. As these furanones were all 301 
structurally related, it seems likely that differences in activity were dictated by small changes 302 
in chemical structure. The observation that two non-brominated compounds (named NF1 and 303 
NF2), which despite having structural similarity to (Z-4-bromo-5-(bromoethylene-3-304 
methylfurn-2(5H)-one had no effect on either QSI activity or persister cells, suggests that 305 
bromine, specifically, is important for activity against persister cells. However, it should be 306 
noted that these non-brominated furanones did not only differ from the brominated 307 
furanone in their lack of halogen groups, but also in the abundance and position of other side 308 
groups. For example, the non-brominated furanone NF2 contained a methoxy group, which 309 
was not present in the brominated furanone. Additionally, furanone NF1 had an additional 310 
carbonyl group, which is not present on the brominated furanone. These changes will have 311 





seen by Pan et al. (2013). Due to these differences, firm conclusions cannot be made 313 
regarding the effect of bromination and furanone activity against persister cells [66].      314 
Mechanism of furanone action 315 
Furanone concentrations of up to 10 µg mL-1 have been demonstrated to reduce expression 316 
of the lasB gene that encodes the LasB elastase, resulting in an approximately 50 % reduction 317 
in relative fluorescence of a PlasB-GFP reporter [54, 57]. This suppression was non-reversible, 318 
even following addition of moderate levels of exogenous autoinducer. Addition of 80 nM 319 
OdDHL and 2 µg mL-1 of C-56 activated lasB expression, while the addition of 40 nM OdDHL 320 
and 2 µg mL-1 C-56 did not. This elegantly demonstrates that the furanone binds competitively 321 
to the native AHL receptor. The possibility of C-56 acting against any other part of the QS 322 
network was ruled out by use of E. coli MT102, which lacks any AHL–mediated QS system 323 
other than the recombinant PlasB-GFP fusion [57]. Reductions in C-56–mediated lasB 324 
expression were also observed in established biofilm as well as in planktonic cultures. Overall, 325 
the experiments suggested that the furanone’s antagonistic activity stems from competition 326 
with the native autoinducer to bind to, and subsequently block, the AHL receptors.   327 
Gene expression studies carried out by Hentzer et al. [58] in PAO1 showed that expression of 328 
85 out of 93 differentially expressed genes was reduced following treatment with furanone 329 
C-30. A large proportion of these genes had previously been described as QS–controlled, 330 
including lasA, lasB and several other genes involved in virulence factor production. 331 
Interestingly, it was shown that expression of fabH1 and fabH2, encoding subunits of the 3-332 
oxo-acyl carrier protein (ACP) synthase III which has been suggested to be involved in the 333 
production of AHL [10, 67], was considerably reduced (~50 and 80–fold, respectively). This 334 





to decreased synthesis of AHL molecules. Genes exhibiting increased expression following C-336 
30 treatment included those of the mexEF-oprN operon that encodes components of a 337 
multidrug efflux pump [68] and genes encoding ATP-binding cassette (ABC) transporters and 338 
major facilitator superfamily (MFS) transporters. These transporter proteins enable both 339 
influx of nutrients and the active removal of toxins from bacterial cells [69, 70] and their 340 
increased expression may be due to the tendency of bacteria to increase efflux activity in the 341 
presence of antimicrobial compounds [71]. Interestingly, expression of mexR, the repressor 342 
for the multidrug resistance efflux pump encoded by mexAB-oprM, exhibited increased 343 
expression (~5–fold) suggesting that, in the presence of the furanone, P. aeruginosa could be 344 
resensitised to certain antibiotics normally excreted by this system.  The expression of the 345 
other mex efflux operon, mexEF-oprN (induced by nitrosative stress and chloramphenicol 346 
[68]) was, however, increased by furanone treatment (>5–fold) and may be consistent with 347 
the cells attempting to actively remove the intracellular furanone.  Hentzer et al.  also showed 348 
that although C-30 did not prevent PAO1 biofilm formation, it exerted a significant effect on 349 
the sensitivity of 72 hour biofilms to 10 µM tobramycin as demonstrated via BacLight staining 350 
[58]. The possibility of furanone–mediated re–sensitisation of PAO1 to antibiotics was not, 351 
however, further investigated by the authors.  352 
This reduction in QS–associated gene expression does not appear to be universal for all QS 353 
systems. The work of Shetye et al. on the P. aeruginosa Rhl QS system utilised E. coli 354 
containing a PrhlI-LVA-GFP reporter plasmid. Treatment with 100 µM to 200 µM of either of 355 
two synthetic brominated furanones caused an increase in fluorescence intensity (caused by 356 
increased transcription of the rhlI-LVA-GFP genes) rather than an antagonistic effect. Thus, 357 
treatment with 200 µM furanone BF15 more than doubled transcription of the PrhlI-LVA-GFP 358 





reduced by approximately 50 % by the same treatment [54]. This observation provides further 360 
evidence that furanone action on QS systems is highly variable, reinforcing the idea that their 361 
effects may not always be antagonistic. The authors hypothesised that, in the light of similar 362 
effects caused by minor structural changes to native signalling molecules, a low binding 363 
constant between the synthetic furanones and their cognate receptors could explain their 364 
observations. This hypothesis is further supported by data from molecular docking studies–365 
an important tool  in the process of novel drug discovery and characterisation [72] and which 366 
have been used to good effect in the search for bioactive furanone compounds. Liu et al. 367 
(2012) demonstrated that furanones associate with the LasR receptor protein in a number of 368 
ways depending on the structure of the given furanone. Synthetic furanones generally 369 
associate with the LasR protein via hydrogen bonding between the carbonyl group on the 370 
furan ring and the amine functional group of Arg 61 in the LasR receptor protein.  Several 371 
other potential furanone–receptor binding sites were identified in silico within both the 372 
receptor protein itself and also in furanone molecules. However, these were unique to the 373 
furanones tested [73]. This work clearly shows that the affinity of a furanone for a receptor 374 
protein is likely to be highly dependent on furanone structure. This further supports the 375 
hypothesis put forward by Shetye et al. [54] that reduced affinity for the receptor may have 376 
caused the agonistic activity of their synthetic furanone lacking a hydrocarbon chain. These 377 
studies provide evidence that while many furanones may show antagonistic behaviour 378 
towards P. aeruginosa QS systems, it is by no means a universal rule.  379 
Further evidence for the importance of furanone structure and its relationship to biological 380 
effect was provided by Brackman et al. in 2012 [74]. They demonstrated that a group of 381 
synthetic AHL derivatives known as triazolyldihydrofuranones, in which the amide function is 382 





biosensor strain of P. aeruginosa. The furanones’ activity was dependent on the length of the 384 
carbon chain bound to the furan ring and compounds with C10 or C12 chains inhibited OdDHL–385 
mediated QS most effectively. It was suggested that this was due to the similar side chain 386 
length (C12) found on the native signalling molecule and indeed the effect of chain length has 387 
also been highlighted in examinations of QSI with other AHL derivatives [75, 76]. It is 388 
important to note that the primary AHL molecules used in Lux, Las and Rhl QS systems all 389 
have carbon chains attached to their five–membered ring and it may follow that the closer 390 
the furanone structure is to the native AHL for the system, the more effectively it can inhibit 391 
that particular QS system. This hypothesis is supported by the work of Ahumendo 392 
Monterrossa et al. [77] who showed that the location and orientation of the AHL side chain 393 
within the LasR receptor is correlated with the biological activity of the ligand. Changes in 394 
ligand functional groups result in agonistic or antagonistic changes in ligand effect, with the 395 
interaction between the AHL acyl side chain and Tyr 47 in LasR dictating the stability of the 396 
resultant AHL–LasR complex. The lack of a side chain similar to that of the native AHL (for 397 
example, a shorter, or absent carbon chain) may result in a furanone not complexing as well 398 
with the LasR receptor, leading to a less potent effect [77]. 399 
While many studies have focused on the synthesis and testing of furanone compounds with 400 
different structures, such as the work of Chang et al. (2019) [78], the compounds in these 401 
studies often differ in more than one structure and it is difficult to ascertain which structural 402 
moiety is impacting on the QSI capability of the molecule. It is also often the case that studies 403 
in which large numbers of furanone derivatives do not extensively test the QSI potential of 404 
the derivatives with many using decreases in biofilm formation (as measured by a simple 405 





is most often the most effective compounds and no direct comparison can be made between 407 
those moieties that increase efficacy and those that do not.  408 
It is clear that the structure of a furanone derivative has an impact on the QSI efficacy of the 409 
compound. Unfortunately, no concerted effort to elucidate the exact structure function 410 
relationship of various side groups and, thus, further research is needed. 411 
Although, the structure of a given furanone undoubtedly has a significant effect on the 412 
bioactivity of the compound, the structure of the target receptor protein will also have an 413 
impact on the QSI ability. Gram negative bacteria typically employ two types of QS receptor 414 
proteins, namely transmembrane, two component, LuxN type receptors and the cytoplasmic 415 
LuxR family of receptors, which typically consist of an AHL binding domain and a DNA binding 416 
domain [79, 80]. There is a high degree of variability between the receptor proteins of 417 
different QS systems and even greater variability between receptors of different species. For 418 
example, while the LasR receptor protein of P. aeruginosa has a high structural similarity to 419 
the TraR receptor of Agroacterium tumefaciens and the SdiA protein from E.coli the amino 420 
acid sequence only sows a 10-16% similarity [81]. It likely that although these receptor 421 
proteins share similar topology the way in which they bind AHL and, therefore furanones, is 422 
likely quite different.  423 
This variability in protein structure is also seen between receptor proteins from different QS 424 
systems from the same organisms.  For example, despite both LasR and RhlR being from P. 425 
aeruginosa, both being activated by structurally similar AHL and thus being closely linked, 426 
RhlR (of which no structure and therefore no specific ligand binding data, has been 427 
elucidated) actually shares a higher sequence homology with the more distant SdiA receptor 428 





mechanisms of ligand binding are quite distinct. Taken together, data from a variety of 430 
molecular investigations suggest that the effects of furanones on QS systems is variable. It is 431 
clear that not only can furanones interact with a number of different QS systems, but also 432 
that they may do so with varying degrees of success and that, furthermore, this efficacy is 433 
influenced by a range of structural factors both in the structure of the furanone, including 434 
carbon chain length and the type of functional side groups found on the lactone ring and 435 
structural differences in the target receptor proteins.   436 
Efficacy of furanones in vivo.   437 
Considering the useful biological effects of furanone QS antagonists on in vitro systems, there 438 
is clear potential for their application to in vivo systems. However, there is a lack of data 439 
regarding their efficacy or safety in vivo, in addition to a certain amount of contradiction 440 
amongst the reports published to date. In 2003, Hentzer et al. showed that, in a mouse model 441 
of 48 h P. aeruginosa lung infection, the intravenous administration of the synthetic furanone 442 
C-30 at a concentration of 1.7 µg g-1 body weight resulted in a reduction in bacterial QS in the 443 
lung tissue, as measured via a lasB-GFP reporter. However, this inhibition was not permanent 444 
and QS recovered to pre–treatment levels after approximately 6 hours. Given the transient 445 
nature of the effect, further experiments showed that a subcutaneous dose of C-30 (0.7 µg g-446 
1 body weight) administered every 8 hours for 3 days immediately following infection with 447 
PAO1 enabled the mice to better clear PAO1 from the lungs when compared to a vehicle 448 
control [58]. This was later confirmed by Wu et al. in 2004 [83] who demonstrated that 449 
intravenous administration of 17 µg g-1 body weight of the synthetic furanone C-56, 24 hours 450 
post–PAO1 infection, resulted in a significant reduction in QS in murine lung tissue as 451 





mediated reduction was only temporary and QS levels returned to baseline values after 453 
approximately 8 hours. Additionally, Wu et al. (2004) showed that oral–as opposed to 454 
subcutaneous–administration of 5 µg g-1 body weight of C-56 resulted in a significant decrease 455 
in both QS in the lung and in mouse mortality. Following infection with a lethal dose of PAO1 456 
and treatment with 5 µg g-1 C-56 three times a day for 2 days, mouse survival increased from 457 
12 % to 45 % at 48 hours post–infection. In contrast to the intravenous administration of C-458 
30 in the work of Hentzer et al. [58], Wu et al. used subcutaneous administration of between 459 
0.25 µg g-1 and 0.7 µg g-1 C-30 three times a day for 3 days. This resulted in significantly better 460 
bacterial clearance from the lung at 7 days post–infection in mice infected with sub-lethal 461 
doses of PAO1, where 1000–fold lower lung CFU numbers resulted following C-30 treatment. 462 
Although no survival rate data was provided for C-30 treated animals, this furanone was more 463 
effective in assisting with bacterial lung clearance than furanone C-56. Furanone–treated 464 
mice also exhibited less severe lung pathology, with fewer abscesses forming in the C-30 465 
treated mice and less tissue damage in the C-56 group. These studies show that not only were 466 
C-30 and C-56 effectively carried to the lungs following oral, intravenous and subcutaneous 467 
administration, but also that they retained their biological activity. Thus, it is clear that both 468 
C-30 and C-56 may be highly beneficial in combatting P. aeruginosa lung infections in vivo.  469 
There is evidence that, in a primary human airway epithelial cell infection model, the natural 470 
furanone, HDMF, may be beneficial. It is known that P. aeruginosa diffusible virulence factors 471 
(e.g. LasA protease, LasB elastase) impair several important functions in airway epithelial cells 472 
including wound healing and cell proliferation and migration [84]. However, in 2016 Ruffin et 473 
al. [85]showed that growth of PAO1 in media supplemented with 125 µg mL-1 HDMF led to 474 
reduced secretion of virulence factors, highlighted by a 70 % decrease in elastase activity 475 





epithelial cell scratch assays were significantly better when exposed to diffusible materials 477 
from HDMF–treated PAO1 cells than when exposed to the secretions from untreated PAO1 478 
cells. Diffusible materials from non-furanone-treated PAO1 reduced the wound repair rate by 479 
~50 %, while repair rates for cells exposed to diffusible material from HDMF–treated PAO1 480 
cells was not significantly different from the controls. This would suggest that HDMF 481 
treatment decreased QS, resulting in a decrease in virulence factor production leading to 482 
better outcomes in wound repair. A similar result was obtained with highly differentiated 483 
airway epithelial cells, indicating the possible utility of HDMF in the treatment of lung 484 
infections, especially given that exposure to HDMF alone did not have a negative impact on 485 
the wound healing capacity of airway epithelial cells [85]. While HDMF apparently reduces 486 
bacterial virulence factor secretion, it is unfortunate that, to date, no data have been 487 
published regarding the cellular toxicity of HDMF. However, it could be hypothesised that 488 
because wound repair rates were not negatively impacted by HDMF, that cell viability also 489 
was not significantly impacted. Nonetheless, further investigation into the cytotoxicity of 490 
HDMF is needed to confirm this.  491 
Furanones as potential therapeutics  492 
The published evidence for the efficacy of furanones in murine models is somewhat limited, 493 
but together with the in vitro human cell data, it suggests that these compounds have 494 
potential as effective human therapeutics. A number of studies have attempted to use 495 
furanones in a clinically relevant way. For example, in 2012 Kim et al. demonstrated that co–496 
administration of furanone with ciprofloxacin significantly reduced in vitro biofilm formation 497 
using a medical implant as a substratum. The dual administration of 50 µg mL-1 5-hydroxy-498 





cells and also effectively prevented P. aeruginosa biofilms from forming on silicone 500 
tympanostomy tubes. While the combination therapy prevented biofilm formation, 501 
treatment with the furanone only led to a reduced level of biofilm formation without a 502 
simultaneous reduction in planktonic cell numbers[26]. Thus, the presence of the furanone 503 
appeared to inhibit biofilm effectively–most likely by interfering with QS signalling– allowing 504 
the antibiotic unrestricted access to planktonic cells. It is likely that when furanone treatment 505 
is stopped, however, that planktonic cells will then begin to form biofilms once again, making 506 
dual treatment necessary. 507 
Siebert et al. (2016) recently suggested that chemical conjugation of furanones to other drugs 508 
currently in use might facilitate development of single molecule, multiple effect treatments.  509 
For example, a synthetic brominated 2(5H) furanone was joined with rosiglitazone, a common 510 
antidiabetic drug also known to have anti-inflammatory properties [86]. The furanone was 511 
linked to a rosiglitazone skeleton in an attempt to combine the QSI properties of the furanone 512 
with the anti-inflammatory properties of rosiglitazone. This combination of effects could be 513 
very useful in treating chronic infections, such as those found in wounds, where biofilm 514 
formation often causes a prolonged inflammatory state [87]. Xu et al. (2018) showed that 515 
treatment with 10 µM rosiglitazone–furanone fusion inhibited QS by up to 50% across the 516 
Las, Rhl and PQS quorum sensing systems as shown by a reduction in fluorescence of PAO1 517 
lasB-GFP, rhlA-GFP and pqsA-GFP reporter strains, respectively. In addition they observed a 518 
reduction in the pro–inflammatory cytokines Tissue Necrosis Factor–α (TNF-α) and 519 
Interleukin–6 (IL-6)in RAW264.7 murine macrophages, showing that the rosiglitazone–520 
furanone compound simultaneously inhibited QS and achieved anti-inflammatory effects 521 
[88]. Thus, while effective on their own, furanones have the potential to be combined with 522 





Bacterial resistance to furanones 524 
One of the main reasons furanones are so attractive to researchers investigating quorum 525 
sensing inhibition is the fact that furanones do not significantly affect bacterial numbers and 526 
show no significant impact on bacterial growth kinetics when used in low doses [58, 89].  527 
As with antibiotics, the issue of resistance to furanones, and quorum sensing inhibitors in 528 
general must always be considered. It has often been stated, when discussing the use of QSI 529 
compounds, that as inhibition of bacterial signalling may constitute a reduced evolutionary 530 
pressure and present less risk of resistance developing [58, 90, 91]. However, it has become 531 
apparent in recent years that this may not be the case.  In 2012 Maeda et al. demonstrated 532 
that P. aeruginosa PA14 transposon mutants with a high resistance to furanone C-30 had 533 
disruptions in the in the mexR gene, which acts as a repressor of the mexAB-OprM operon. 534 
This mutation causes an overproduction of the MexAB-OprM efflux pump, suggesting a role 535 
for heightened efflux in resistance against this furanone [92]. This work was further supported 536 
by the work of García-Contreras et al. who, in 2013, assessed the effect of C-30 on virulence 537 
factor production in 50 clinical strains of P. aeruginosa isolated from cystic fibrosis patients. 538 
They found that while many clinical isolates responded to C-30 with greatly reduced elastase 539 
and pyocyanin production, several strains showed either no decrease in virulence factor 540 
production, or exhibited an increase in production of greater than 100 %. One strain in 541 
particular IP-42 exhibited significantly higher C-30 efflux capacity, while two other strains had 542 
significantly decreased C-30 uptake. While the reason for this decreased uptake is not known, 543 
the authors suggested a possible mutation in a transporter protein which they say “have not 544 
yet been identified” [93]. Despite many strains responding to C-30 as expected, with 545 





used with caution in the clinical setting as many resistant strains may already exist, with–in 547 
extreme cases–the furanone compound exacerbating the infection.  548 
Resistance may also arise through mutations and changes that do not occur in the quorum 549 
sensing system “circuit”. It has been previously reported by Feltner et al. in 2016 that some 550 
clinical isolates of P. aeruginosa show variations in nucleotide sequence of the lasR gene of 551 
the Las QS system [94]. These isolates were obtained from cystic fibrosis respiratory cultures 552 
during the EPIC study [95], and when their lasR genes sequenced, 22% of the genes encoded 553 
a LasR protein that was significantly different to that of laboratory strains of P. aeruginosa 554 
also analysed. The mutations included insertions, deletions and single nucleotide 555 
polymorphisms (resulting in either amino acid changes or stop codons leading to truncated 556 
proteins). These LasR variants were either functionally different, or non-functional (LasR 557 
deficient). However, the most interesting finding of this study was that in the LasR deficient 558 
variants there was no significant change in a number of QS related phenotypes, such as 559 
motility or pyocyanin production. The authors then showed that the expression of some QS 560 
related phenotypes was maintained by the Rhl QS system in the absence of a functional LasR 561 
protein. This study demonstrated that clinical isolates can possess mutations that cause a 562 
‘rewiring’ of the QS systems and their regulation. This presents a significant problem for the 563 
use of furanones, and other QSI, as a potential therapeutic as targeting a specific QS system 564 
may not be an effective treatment in such QS variants.  565 
While resistance to furanones and QSI in general may be the result of repeated exposure, 566 
altered compound transport into and out of bacterial cells or mutations in the QS system 567 
genes themselves it is clear that the use of furanones may not be a universally effective 568 






Outstanding questions 571 
While many advances have been made in the use of furanones as QSIs and potential 572 
therapeutics several important questions remain unanswered. Firstly, do all furanones exert 573 
their QSI effects via the same mechanism and what effect does furanone structure have on 574 
the mode of action? Characterisation of structural indicators of efficacy using a furanone 575 
compound library and fluorescent QS reporter strains may help to develop a method for rapid 576 
identification of potentially useful furanone compounds or provide opportunities to modify 577 
current compounds to increase efficacy.  578 
If furanones are to be used in humans as a therapeutic agent the effect of therapeutic 579 
concentrations of furanones on mammalian cells must be investigated. Further 580 
experimentation is needed to elucidate any deleterious effects on human cells in relation to 581 
protein production, cell proliferation and release of inflammatory mediators. Additionally, 582 
will the positive effects seen with in vitro studies and in the small number of mouse models 583 
translate to use in humans? If furanones are not shown to be detrimental to human cell lines, 584 
will their efficacy translate to systemic use or will drug activity be lost due to their metabolism 585 
in the liver or clearance by the kidneys? 586 
While furanones are thought to be effective against pathogens at non-lethal concentrations, 587 
it is unclear if resistance to furanones can be avoided by using sub inhibitory concentrations? 588 
What are the potential mechanisms of furanone resistance? For example, would mutations 589 
in Las and Rhl receptors result in furanones not being able to bind effectively, or does 590 
increased efflux capacity allow the cells to better remove furanones? If resistance is 591 





Another important consideration is the route of administration of these compounds. How 593 
could furanones be administered effectively to combat infections in which quorum sensing 594 
and quorum sensing controlled behaviours are a significant problem? Does method of 595 
delivery significantly impact the efficacy of the compounds? 596 
Finally, there is the issue of off target effects arising from furanone therapy. What, if any, are 597 
the effects of topical and systemic use of quorum sensing inhibitors on the microbiome? It is 598 
known that many microbial communities, such as those found on the skin and in the gut, are 599 
dependent on effective quorum sensing and, to date, it is unclear what the effect of using 600 
quorum sensing inhibitors such as furanones on these communities would be.   601 
 602 
Concluding remarks 603 
Quorum sensing is a method of cell–cell communication responsible for the production of 604 
numerous virulence factors and the coordination of complex bacterial behaviours such as 605 
biofilm formation. Quorum sensing and its related processes have been shown to be involved 606 
in the formation and maintenance of a range of clinically relevant infections. In recent years 607 
numerous compounds, including furanones, have been investigated for their ability to 608 
interfere or inhibit the process of quorum sensing. Furanones have been demonstrated to 609 
significantly decrease virulence factor production and biofilm formation in a range of 610 
environmental and clinical pathogens. However, concerns have been raised surrounding both 611 
the potentially negative effects of furanones on human cells and the possibility of developing 612 
resistance. The material considered in this review clearly demonstrates that while both 613 
natural and synthetic furanones have great potential as novel antimicrobial therapeutics, 614 





the efficacy of furanones as therapeutic agents in animal models are required as well as 616 
research into novel delivery methods for the compounds themselves. Critically, investigations 617 
are also needed regarding possible adverse effects on mammalian cells. If these issues are 618 
addressed it is clear that furanones may prove to have excellent potential in combatting 619 
bacterial infections in an age of widespread antimicrobial resistance.       620 





Statement of Conflict 622 






















1. Fuqua WC, Winans SC, Greenberg EP. Quorum sensing in bacteria: The LuxR-LuxI 641 
family of cell density- responsive transcriptional regulators. J Bacteriol 1994;176:269–642 
275. 643 
2. Seed PC, Passador L, Iglewski BH. Activation of the Pseudomonas aeruginosa lasI 644 
gene by LasR and the Pseudomonas autoinducer PAI: An autoinduction regulatory 645 
hierarchy. J Bacteriol 1995;177:654–659. 646 
3. Cvitkovitch DG, Li Y-H, Ellen RP. Quorum sensing and biofilm formation in 647 
Streptococcal infections. J Clin Invest 2003;112:1626–32. 648 
4. Lynch MJ, Swift S, Kirke DF, Keevil CW, Dodd CER, et al. The regulation of biofilm 649 
development by quorum sensing in Aeromonas hydrophila. Environ Microbiol 650 
2002;4:18–28. 651 
5. Hammer BK, Bassler BL. Quorum sensing controls biofilm formation in Vibrio 652 
cholerae. Mol Microbiol 2003;50:101–4. 653 
6. Labbate M, Queck SY, Koh KS, Rice SA, Givskov M, et al. Quorum sensing-controlled 654 
biofilm development in Serratia liquefaciens MG1. J Bacteriol 2004;186:692–8. 655 
7. Rice SA, Koh KS, Queck SY, Labbate M, Lam KW, et al. Biofilm formation and 656 
sloughing in Serratia marcescens are controlled by quorum sensing and nutrient cues. 657 
J Bacteriol 2005;187:3477–85. 658 
8. Kohler T, Curty LK, Barja F, Van Delden C, Pechere JC. Swarming of Pseudomonas 659 
aeruginosa is dependent on cell-to-cell signaling and requires flagella and pili. J 660 
Bacteriol 2000;182:5990–5996. 661 





sensing in the plant pathogen Erwinia carotovora subsp. carotovora: The eole of expR 663 
Ecc. Mol Plant-Microbe Interact MPMI 2000;13:384–393. 664 
10. Parsek MR, Val DL, Hanzelka BL, Cronan JE, Greenberg EP. Acyl homoserine-lactone 665 
quorum-sensing signal generation. Proc Natl Acad Sci U S A 1999;96:4360–5. 666 
11. Gambello MJ, Kaye S, Iglewski BH. LasR of Pseudomonas aeruginosa is a 667 
transcriptional activator of the alkaline protease gene (apr) and an enhancer of 668 
exotoxin A expression. Infect Immun 1993;61:1180–4. 669 
12. Gambello MJ, Iglewski BH. Cloning and characterization of the Pseudomonas 670 
aeruginosa lasR gene, a transcriptional activator of elastase expression. J Bacteriol 671 
1991;173:3000–9. 672 
13. Schuster M, Lostroh CP, Ogi T, Greenberg EP. Identification, timing, and signal 673 
specificity of Pseudomonas aeruginosa quorum-controlled genes: a transcriptome 674 
analysis. J Bacteriol 2003;185:2066–2079. 675 
14. Arevalo-Ferro C, Hentzer M, Reil G, Görg A, Kjelleberg S, et al. Identification of 676 
quorum-sensing regulated proteins in the opportunistic pathogen Pseudomonas 677 
aeruginosa by proteomics. Environ Microbiol 2003;5:1350–69. 678 
15. Lee J, Wu J, Deng Y, Wang JJ, Wang C, et al. A cell-cell communication signal 679 
integrates quorum sensing and stress response. Nat Chem Biol 2013;9:339–343. 680 
16. Toder DS, Gambello MJ, Iglewski BH. Pseudomonas aeruginosa LasA: a second 681 
elastase under the transcriptional control of lasR. Mol Microbiol 1991;5:2003–10. 682 
17. Pesci EC, Pearson JP, Seed PC, Iglewski BH. Regulation of las and rhl quorum sensing 683 





18. Latifi A, Foglino M, Tanaka K, Williams P, Lazdunski A. A hierarchical quorum-sensing 685 
cascade in Pseudomonas aeruginosa links the transcriptional activators LasR and RhIR 686 
(VsmR) to expression of the stationary-phase sigma factor RpoS. Mol Microbiol 687 
1996;21:1137–1146. 688 
19. Wade DS, Calfee MW, Rocha ER, Ling EA, Engstrom E, et al. Regulation of 689 
Pseudomonas quinolone signal synthesis in Pseudomonas aeruginosa. J Bacteriol 690 
2005;187:4372–80. 691 
20. Pearson JP, Pesci EC, Iglewski BH. Roles of Pseudomonas aeruginosa las and rhl 692 
quorum-sensing systems in control of elastase and rhamnolipid biosynthesis genes. J 693 
Bacteriol 1997;179:5756–67. 694 
21. Pessi G, Haas D. Transcriptional control of the hydrogen cyanide biosynthetic genes 695 
hcnABC by the anaerobic regulator ANR and the quorum-sensing regulators LasR and 696 
RhlR in Pseudomonas aeruginosa. J Bacteriol 2000;182:6940–9. 697 
22. Rutherford ST, Bassler BL. Bacterial quorum sensing: its role in virulence and 698 
possibilities for its control. Cold Spring Harb Perspect Med 2012;2:1–25. 699 
23. Papenfort K, Bassler BL. Quorum sensing signal–response systems in gram-negative 700 
bacteria. Nat Rev Microbiol 2016;14:576–588. 701 
24. Lee J, Zhang L. The hierarchy quorum sensing network in Pseudomonas aeruginosa. 702 
Protein Cell 2015;6:26–41. 703 
25. Koutsoudis M, Tsaltas D, Minogue T, von Bodman S. Quorum-sensing regulation 704 
governs bacterial adhesion, biofilm development, and host colonization in Pantoea 705 





26. Kim SG, Yoon YH, Choi JW, Rha KS, Park YH. Effect of furanone on experimentally 707 
induced Pseudomonas aeruginosa biofilm formation: In vitro study. Int J Pediatr 708 
Otorhinolaryngol 2012;76:1575–1578. 709 
27. Keays T, Ferris W, Vandemheen KL, Chan F, Yeung S-W, et al. A retrospective 710 
analysis of biofilm antibiotic susceptibility testing: A better predictor of clinical 711 
response in cystic fibrosis exacerbations. J Cyst Fibros 2009;8:122–127. 712 
28. McCarty SM, Percival SL. Proteases and delayed wound healing. Adv wound care 713 
2013;2:438–447. 714 
29. Flemming H-C, Wingender J, Szewzyk U, Steinberg P, Rice SA, et al. Biofilms: an 715 
emergent form of bacterial life. Nat Rev Microbiol 2016;14:563–575. 716 
30. Crouzet M, Claverol S, Lomenech AM, Le Sénéchal C, Costaglioli P, et al. 717 
Pseudomonas aeruginosa cells attached to a surface display a typical proteome early 718 
as 20 minutes of incubation. PLoS One 2017;12:1–24. 719 
31. Siryaporn A, Kuchma SL, O’Toole GA, Gitai Z, Ausubel FM. Surface attachment 720 
induces Pseudomonas aeruginosa virulence. Proc Natl Acad Sci U S A 721 
2014;111:16860–16865. 722 
32. Davey ME, Caiazza NC, O’Toole GA. Rhamnolipid surfactant production affects 723 
biofilm architecture in Pseudomonas aeruginosa PAO1. J Bacteriol 2003;185:1027–36. 724 
33. Sauer K, Cullen MC, Rickard AH, Zeef LAH, Davies DG, et al. Characterization of 725 
nutrient-induced dispersion in Pseudomonas aeruginosa PAO1 biofilm. J Bacteriol 726 
2004;186:7312–7326. 727 





aeruginosa biofilm development. Mol Microbiol 1998;30:295–304. 729 
35. Brackman G, Coenye T. Quorum sensing inhibitors as anti-biofilm agents. Curr Pharm 730 
Des 2015;21:5–11. 731 
36. de Nys R, Wright AD, König GM, Sticher O. New halogenated furanones from the 732 
marine alga delisea pulchra (cf. fimbriata). Tetrahedron 1993;49:11213–11220. 733 
37. Slaughter JC. The naturally occurring furanones: Formation and function from 734 
pheromone to food. Biol Rev 1999;74:259–276. 735 
38. Arihara K, Yokoyama I, Ohata M. DMHF (2,5-dimethyl-4-hydroxy-3(2H)-furanone), a 736 
volatile food component with attractive sensory properties, brings physiological 737 
functions through inhalation. In: Advances in Food and Nutrition Research. Elsevier 738 
Inc.; 2019. pp. 239–258. 739 
39. Wang Y, Ho CT. Formation of 2,5-dimethyl-4-hydroxy-3(2H)-furanone through 740 
methylglyoxal: A maillard reaction intermediate. J Agric Food Chem 2008;56:7405–741 
7409. 742 
40. Dahlen T, Hauck T, Wein M, Schwab W. 2,5-dimethyl-4-hydroxy-3(2H)-furanone as 743 
asecondary metabolite from D-fructose-1,6-diphosphate metabolism by 744 
Zygosaccharomyces rouxii. J Biosci Bioeng 2001;91:352–358. 745 
41. Phainuphong P, Rukachaisirikul V, Tadpetch K, Sukpondma Y, Saithong S, et al. γ-746 
Butenolide and furanone derivatives from the soil-derived fungus Aspergillus 747 
sclerotiorum PSU-RSPG178. Phytochemistry 2017;137:165–173. 748 
42. Tanabe Y, Ohno N. A novel and efficient synthesis of 2(5H)-furanone derivatives. J 749 





43. Caine D, Ukachukwu V. A New synthesis of 3-n-Butyl-4-bromo-5(Z)-751 
(bromomethylidene)-2-95H)-furanone, a naturally occurring fimbriolide from Delisia 752 
fimbriata (Bonnemaisoniaceae). J Org Chem 1985;50:2195–2198. 753 
44. Rodin JO, Himel CM, Silverstein RM, Leeper RW, Gortner WA. Volatile flavor and 754 
aroma components of pineapple. l. Isolation and tentative identification of 2,5-755 
dimethyl-4-hydroxy-3(2H)-furanone. J Food Sci 1965;30:280–285. 756 
45. Kendall EC, Hajos ZG. Tetrahydro-3,4-furandione. I. Preparations and properties. J Am 757 
Chem Soc 1960;82:3219–3220. 758 
46. Nealson KH, Platt T, Hastings JW. Cellular control of the synthesis and activity of the 759 
bacterial luminescent system. J Bacteriol 1970;104:313–22. 760 
47. Eberhard A, Burlingame AL, Eberhard C, Kenyon GL, Nealson KH, et al. Structural 761 
identification of autoinducer of Photobacterium fischeri luciferase. Biochemistry 762 
1981;20:2444–2449. 763 
48. Givskov M, de Nys R, Manefield M, Gram L, Maximilien R, et al. Eukaryotic 764 
interference with homoserine lactone-mediated prokaryotic signalling. J Bacteriol 765 
1996;178:6618–22. 766 
49. Manefield M, de Nys R, Naresh K, Roger R, Givskov M, et al. Evidence that 767 
halogenated furanones from Delisea pulchra inhibit acylated homoserine lactone 768 
(AHL)-mediated gene expression by displacing the AHL signal from its receptor 769 
protein. Microbiology 1999;145:283–291. 770 
50. Manefield M, Welch M, Givskov M, Salmond GPC, Kjelleberg S. Halogenated 771 





and exoenzyme virulence factor production in the phytopathogen Erwinia carotovora. 773 
FEMS Microbiol Lett 2001;205:131–138. 774 
51. Welch M, Todd DE, Whitehead NA, McGowan SJ, Bycroft BW, et al. N-acyl 775 
homoserine lactone binding to the CarR receptor determines quorum-sensing 776 
specificity in Erwinia. EMBO J 2000;19:631–41. 777 
52. McGowan SJ, Barnard AML, Bosgelmez G, Sebaihia M, Simpson NJL, et al. 778 
Carbapenem antibiotic biosynthesis in Erwinia carotovora is regulated by 779 
physiological and genetic factors modulating the quorum sensing-dependent control 780 
pathway. Mol Microbiol 2004;55:526–545. 781 
53. Ren D, Sims JJ, Thomas K, Biology C, Road A. Inhibition of biofilm formation and 782 
swarming of Escherichia coli by ( 5Z ) -4-bromo-5- ( bromomethylene ) -3- butyl-2 ( 5H 783 
) -furanone. Environmental Microbiology, 3(Fujikawa 1994), 731–736. Environ 784 
Microbiol 2001;3:731–736. 785 
54. Shetye GS, Singh N, Gao X, Bandyopadhyay D, Yan A, et al. Structures and biofilm 786 
inhibition activities of brominated furanones for Escherichia coli and Pseudomonas 787 
aeruginosa. Medchemcomm 2013;4:1079. 788 
55. Vestby LKK, Johannesen KCSCS, Witsø ILL, Habimana O, Scheie AAA, et al. Synthetic 789 
brominated furanone F202 prevents biofilm formation by potentially human 790 
pathogenic Escherichia coli O103:H2 and Salmonella ser. Agona on abiotic surfaces. J 791 
Appl Microbiol 2014;116:258–68. 792 
56. Witsø IL, Benneche T, Vestby LK, Nesse LL, Lönn-Stensrud J, et al. Thiophenone and 793 






57. Hentzer M, Riedel K, Rasmussen TB, Heydorn A, Andersen JB, et al. Inhibition of 796 
quorum sensing in Pseudomonas aeruginosa biofilm bacteria by a halogenated 797 
furanone compound. Microbiology 2002;148:87–102. 798 
58. Hentzer M, Wu H, Andersen JB, Riedel K, Rasmussen TB, et al. Attenuation of 799 
Pseudomonas aeruginosa virulence by quorum-sensing inhibitors. Embo J 800 
2003;22:3803. 801 
59. Choi SC, Zhang C, Moon S, Oh YS. Inhibitory effects of 4-hydroxy-2,5-dimethyl-3(2H)-802 
furanone (HDMF) on acyl-homoserine lactone-mediated virulence factor production 803 
and biofilm formation in Pseudomonas aeruginosa PAO1. J Microbiol 2014;52:734–804 
742. 805 
60. Ren D, Zuo R, Wood TK. Quorum-sensing antagonist (5Z)-4-bromo-5-806 
(bromomethylene)-3-butyl-2(5H)- furanone influences siderophore biosynthesis in 807 
Pseudomonas putida and Pseudomonas aeruginosa. Appl Microbiol Biotechnol 808 
2005;66:689–695. 809 
61. Defoirdt T, Miyamoto CM, Wood TK, Meighen EA, Sorgeloos P, et al. The natural 810 
furanone (5Z)-4-bromo-5-(bromomethylene)-3-butyl-2(5H)-furanone disrupts 811 
quorum sensing-regulated gene expression in Vibrio harveyi by decreasing the DNA-812 
binding activity of the transcriptional regulator protein luxR. Environ Microbiol 813 
2007;9:2486–2495. 814 
62. Kim C, Kim J, Park HY, Park HJ, Lee JH, et al. Furanone derivatives as quorum-sensing 815 





63. Mulcahy LR, Burns JL, Lory S, Lewis K. Emergence of Pseudomonas aeruginosa strains 817 
producing high levels of persister cells in patients with cystic fibrosis. J Bacteriol 818 
2010;192:6191–6199. 819 
64. Fauvart M, De Groote VN, Michiels J. Role of persister cells in chronic infections: 820 
clinical relevance and perspectives on anti-persister therapies. J Med Microbiol 821 
2011;60:699–709. 822 
65. Pan J, Bahar AA, Syed H, Ren D. Reverting antibiotic tolerance of Pseudomonas 823 
aeruginosa PAO1 persister cells by (Z)-4-bromo-5-(bromomethylene)-3-methylfuran-824 
2(5H)-one. PLoS One 2012;7:e45778. 825 
66. Pan J, Ren D. Structural effects on persister control by brominated furanones. 826 
Bioorganic Med Chem Lett 2013;23:6559–6562. 827 
67. Schaefer AL, Val DL, Hanzelka BL, Cronan JE, Greenberg EP, et al. Generation of cell-828 
to-cell signals in quorum sensing: acyl homoserine lactone synthase activity of a 829 
purified Vibrio fischeri LuxI protein. Proc Natl Acad Sci U S A 1996;93:9505–9. 830 
68. Fetar H, Gilmour C, Klinoski R, Daigle DM, Dean CR, et al. mexEF-oprN multidrug 831 
efflux operon of Pseudomonas aeruginosa: regulation by the MexT activator in 832 
response to nitrosative stress and chloramphenicol. Antimicrob Agents Chemother 833 
2011;55:508–14. 834 
69. Yan N. Structural biology of the major facilitator superfamily transporters. Annu Rev 835 
Biophys 2015;44:257–283. 836 
70. Kumar S, Mukherjee MM, Varela MF. Modulation of bacterial multidrug resistance 837 





71. Du D, Wang-Kan X, Neuberger A, van Veen HW, Pos KM, et al. Multidrug efflux 839 
pumps: structure, function and regulation. Nat Rev Microbiol 2018;16:523–539. 840 
72. Meng X-Y, Zhang H-X, Mezei M, Cui M. Molecular docking: a powerful approach for 841 
structure-based drug discovery. Curr Comput Aided Drug Des 2011;7:146–57. 842 
73. Liu G-YY, Guo B-QQ, Chen W-MW-NNWM, Cheng C, Zhang Q-LL, et al. Synthesis, 843 
molecular docking, and biofilm formation inhibitory activity of 5-substituted 3,4-844 
dihalo-5H-furan-2-one derivatives on Pseudomonas aeruginosa. Chem Biol Drug Des 845 
2012;79:628–638. 846 
74. Brackman G, Risseeuw M, Celen S, Cos P, Maes L, et al. Synthesis and evaluation of 847 
the quorum sensing inhibitory effect of substituted triazolyldihydrofuranones. 848 
Bioorganic Med Chem 2012;20:4737–4743. 849 
75. Castang S, Chantegrel B, Deshayes C, Dolmazon. Rene, Gouet P, et al. N-Sulfonyl 850 
homoserine lactones as antagonists of bacterial quorum sensing. Bioorganic Med 851 
Chem Lett 2004;14:5145–5149. 852 
76. Boukraa M, Sabbah M, Soulere L, El Efrit M, Queneau Y, et al. AHL-dependent 853 
quorum sensing inhibition: Synthesis and biological evaluation of a-(N-alkyl-854 
carboxamide)-c-butyrolactones and a-(N-alkyl-sulfonamide)-c-butyrolactones. 855 
Bioorganic Med Chem Lett 2011;21:6876–6879. 856 
77. Ahumedo Monterrosa M, Galindo JF, Vergara Lorduy J, Alí-Torres J, Vivas-Reyes R. 857 
The role of LasR active site amino acids in the interaction with the Acyl Homoserine 858 






78. Chang Y, Wang P-C, Ma H-M, Chen S-Y, Fu Y-H, et al. Design, synthesis and 861 
evaluation of halogenated furanone derivatives as quorum sensing inhibitors in 862 
Pseudomonas aeruginosa. Eur J Pharm Sci 2019;105058. 863 
79. Hanzelka BL, Greenberg EP. Evidence that the N-terminal region of the Vibrio fischeri 864 
luxR protein constitutes an autoinducer-binding domain. Journal of Bacteriology 865 
1995;177:815–817. 866 
80. Choi SH, Greenberg EP. The C-terminal region of the Vibrio fischeri LuxR protein 867 
contains an inducer-independent lux gene activating domain. Proc Natl Acad Sci U S A 868 
1991;88:11115–11119. 869 
81. Bottomley MJ, Muraglia E, Bazzo R, Carfì A. Molecular insights into quorum sensing 870 
in the human pathogen Pseudomonas aeruginosa from the structure of the virulence 871 
regulator LasR bound to its autoinducer. J Biol Chem 2007;282:13592–13600. 872 
82. Mukherjee S, Moustafa DA, Stergioula V, Smith CD, Goldberg JB, et al. The PqsE and 873 
RhlR proteins are an autoinducer synthase–receptor pair that control virulence and 874 
biofilm development in Pseudomonas aeruginosa. Proc Natl Acad Sci U S A 875 
2018;115:e9411–e9418. 876 
83. Wu H, Song Z, Hentzer M, Andersen JB, Molin S, et al. Synthetic furanones inhibit 877 
quorum-sensing and enhance bacterial clearance in Pseudomonas aeruginosa lung 878 
infection in mice. J Antimicrob Chemother 2004;53:1054–1061. 879 
84. Ruffin M, Brochiero E. Repair process impairment by Pseudomonas aeruginosa in 880 
epithelial tissues: major features and potential therapeutic avenues. Front Cell Infect 881 





85. Ruffin M, Bilodeau C, Mailĺe É, LaFayette SL, McKay GA, et al. Quorum-sensing 883 
inhibition abrogates the deleterious impact of Pseudomonas aeruginosa on airway 884 
epithelial repair. FASEB J 2016;30:3011–3025. 885 
86. Siebert A, Goren I, Pfeilschifter J, Frank S. Anti-Inflammatory effects of rosiglitazone 886 
in obesity-impaired wound healing depend on adipocyte differentiation. PLoS One 887 
2016;11:e0168562. 888 
87. Attinger C, Wolcott R. Clinically addressing biofilm in chronic wounds. Adv wound 889 
care 2012;1:127–132. 890 
88. Xu X-J, Wang F, Zeng T, Lin J, Liu J, et al. 4-arylamidobenzyl substituted 5-891 
bromomethylene-2(5H)-furanones for chronic bacterial infection. Eur J Med Chem 892 
2018;144:164–178. 893 
89. Janssens JCA, Steenackers H, Robijns S, Gellens E, Levin J, et al. Brominated 894 
furanones inhibit biofilm formation by Salmonella enterica serovar Typhimurium. Appl 895 
Environ Microbiol 2008;74:6639–6648. 896 
90. Rasko DA, Sperandio V. Anti-virulence strategies to combat bacteria-mediated 897 
disease. Nature Reviews Drug Discovery 2010;9:117–128. 898 
91. Bjarnsholt T, Tolker-Nielsen T, Høiby N, Givskov M. Interference of Pseudomonas 899 
aeruginosa signalling and biofilm formation for infection control. Expert Rev Mol 900 
Med;12. Epub ahead of print February 2010. DOI: 10.1017/S1462399410001420. 901 
92. Maeda T, García-Contreras R, Pu M, Sheng L, Garcia LR, et al. Quorum quenching 902 
quandary: resistance to antivirulence compounds. ISME J 2012;6:493–501. 903 





AG, Hashimoto T, et al. Resistance to the quorum-quenching compounds brominated 905 
furanone C-30 and 5-fluorouracil in Pseudomonas aeruginosa clinical isolates. Pathog 906 
Dis 2013;68:8–11. 907 
94. Feltner JB, Wolter DJ, Pope CE, Groleau MC, Smalley NE, et al. LasR variant cystic 908 
fibrosis isolates reveal an adaptable quorum-sensing hierarchy in Pseudomonas 909 
aeruginosa. MBio 2016;7:E01513-e01513. 910 
95. Mayer-Hamblett N, Rosenfeld M, Gibson RL, Ramsey BW, Kulasekara HD, et al. 911 
Pseudomonas aeruginosa in vitro phenotypes distinguish cystic fibrosis infection 912 
stages and outcomes. Am J Respir Crit Care Med 2014;190:289–297. 913 










Figure 2 920 
 921 
 922 
 923 
